HOME >> BIOLOGY >> NEWS
Low dose vitamin A derivative does not prevent head and neck tumors, clinical trial finds

Taking a vitamin A derivative called isotretinoin did not reduce the risk of second primary tumors or improve survival in patients with stage I or II head and neck squamous cell cancers (HNSCC), according to a study in the April 5 issue of the Journal of the National Cancer Institute. In addition, current smokers had an increased risk of second primary cancers and death.

HNSCCs are the fifth most common cancers and sixth leading cause of cancer related death today. In 2002, there were 600,000 new cases diagnosed worldwide. Some studies have suggested that vitamin A derivatives called retinoids may halt or even reverse growth of head and neck tumors. A clinical trial of high doses of a retinoid called isotretinoin, widely used to treat cystic acne, in patients with HNSCC found that those receiving isotretinoin developed fewer second primary tumors, particularly smoking-related tumors. However, there were substantial side effects among those who received the high-dose isotretinoin, and subsequent studies of the compound have shown mixed results.

To assess the effect of lower, more tolerable doses of isotretinoin on the development of second primary tumors and survival among patients with early-stage HNSCC, Fadlo R. Khuri, M.D., of the Emory University School of Medicine in Atlanta, and colleagues conducted a randomized clinical trial of 1190 patients diagnosed with stage I or II HNSCC. Patients were randomly assigned to receive low-dose isotretinoin (30 mg/day) or a placebo for 3 years. They continued to monitor the patients for 4 or more years after treatment. This clinical trial is the largest chemoprevention study to date to examine the use of retinoids in patients with early-stage HNSCC.

The study found that low-dose isotretinoin did not reduce the rate of second primary tumors or improve overall survival compared with a placebo. Current smokers in both the treatment and placebo groups had an increased rate of second primary tu
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
4-Apr-2006


Page: 1 2

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Lack of sun does not explain low vitamin D in elderly who are overweight
3. Dietary vitamin B6, B12 and folate, may decrease pancreatic cancer risk among lean people
4. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
5. Heavy multivitamin use may be linked to advanced prostate cancer
6. MIT biologists solve vitamin puzzle
7. High levels of vitamin D in the body may decrease the risk of multiple sclerosis
8. Einstein researchers discover how a key dietary vitamin is absorbed
9. Poor athletic performance linked to vitamin deficiency
10. Super chow, laced with semi-synthetic vitamin E derivative, inhibited spread of cancer in mice
11. Prenatal vitamins may reduce risk of brain tumors in children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... ... June 04, 2019 , ... Lajollacooks4u is delighted to announce it ... which honors hospitality excellence, is given only to businesses that have achieved consistently outstanding ... consecutive years. , To qualify for the Certificate of Excellence –- an ...
(Date:6/1/2019)... ... May 31, 2019 , ... The University ... recently invested in BioFactura’s $6M Series B Financing Round. , “With the ... investors who bring significant financial and business resources to bear as we advance ...
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers from Ambry ... documented significant differences in the prevalence of hereditary genetic mutations, also called germline ... White women. Results will be presented at the 2019 American Society of Clinical ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... California (PRWEB) , ... May ... ... of our patent applications from the USPTO providing proprietary interest to our ... METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including ...
(Date:5/22/2019)... ... 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation Management ... co-led by Astanor Ventures and Talis Capital with participation from ... Fund . The company has raised $11.75m to date and will use the new ...
(Date:5/14/2019)... ... May 13, 2019 , ... ... testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is ... redesigned website aims to improve LDA’s ability to communicate directly with the marketplace; ...
(Date:5/4/2019)... Brazil (PRWEB) , ... May 03, 2019 , ... ... given by the President of the Dakila Pesquisas Association, the scientist and ufologist ... Councilmen 2019, in Brasília (DF). Urandir detailed the results of some research carried ...
Breaking Biology Technology:
Cached News: